Novartis beats expectations for third quarter

Core earnings per share ended the period at a higher level than analysts' estimates for Novartis's Q3.

Photo: Arnd Wiegmann/Reuters/Ritzau Scanpix

BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN

Published: 26.10.21 at 09:06

Novartis finishes the third quarter of the year better than analysts had anticipated, including outperforming in core earnings per share (EPS), reports Bloomberg News.

Consensus estimates collected by Bloomberg News put Novartis's net sales at USD 13bn, but Novartis has marginally exceeded that figure with reported Q3 net sales figures of USD 13.03bn.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.